Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to receptors on ovarian granulosa cells, promoting follicular growth and estradiol synthesis. The LH component activates receptors on theca cells and mature follicles, triggering ovulation and luteal phase steroid production. Together they mimic the natural pituitary signal that drives normal ovarian function.

The dosage of Meriofert is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s specific condition, response to treatment and protocol requirements. No standard dose is provided in public information.

Meriofert is intended for use before conception to facilitate ovulation and embryo development. It is not recommended for use during an established pregnancy, and safety data for breastfeeding are insufficient. Treatment should be discontinued once pregnancy is confirmed, and breastfeeding decisions should follow a physician’s guidance.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Meriofert combines both FSH and LH in a single injectable formulation, whereas some alternatives provide only recombinant FSH or separate LH preparations. The combined approach can simplify dosing schedules and may better mimic natural pituitary output, but selection depends on the specific clinical protocol, patient response and physician preference.

Meriofert must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it may be used, but it should be returned to the refrigerator promptly.

Meriofert is supplied as a sterile solution for injection. It is administered either intramuscularly or subcutaneously according to the prescribing clinician’s instructions. The injection site is typically the abdomen or thigh, and aseptic technique should be observed for each dose.

The most serious adverse events include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, fluid accumulation and respiratory compromise, as well as thromboembolic complications, allergic reactions such as anaphylaxis, and the possibility of multiple or ectopic pregnancies. Prompt medical evaluation is required if any of these occur.

Meriofert is contraindicated in individuals with known hypersensitivity to FSH, LH or any excipients in the formulation, in patients with active ovarian cysts, uncontrolled thyroid disease, or a history of severe ovarian hyperstimulation syndrome. It should also be avoided in women who are already pregnant.